CMD’s magneto-optical detection platform is fast and adaptable, providing broad detection capabilities

Beyond endotoxin, the CMD platform is capable of detecting a range of markers at point-of-need. The technology allows for sensing in two modes - passive and active.

In passive mode, the CMD technology monitors changes in a sample matrix that occur as a result of clotting, agglutination, aggregation and coagulation processes, whilst in active mode, the use of conventional targeting / receptor moieties such as antibodies, primers and peptides, allow for the quantitative detection of markers for interest.

CMD has demonstrated the ability to detect clinical biomarkers associated with infection and inflammation in a matter of minutes using the active sensing mode.